New Atrial Fibrillation After TAVR Indicates Prognosis

Courtesy of Dr. Carlos Fava.

Transcatheter aortic valve replacement (TAVR) has emerged as an important treatment alternative for intermediate- and high-risk patients. In that sense, the presence of atrial fibrillation (AF) before TAVR is high and it has been associated with worse outcomes and higher mortality. However, there is not much evidence available regarding new-onset atrial fibrillation after TAVR. We ignore its implications and the best course of treatment (whether pharmacological or invasive).

TAVI vs. SAVRThis study analyzed 13,356 patients who underwent TAVR. Among them, 1138 (8.4%) developed new AF (NAF) after percutaneous valve implantation.

 

The characteristics of both groups were similar, although patients with NAF presented the following particular features: patients were older (with a higher percentage of female subjects) and had higher rates of chronic obstructive pulmonary disease (COPD), higher Society of Thoracic Surgery predicted risk of mortality score (6.5 vs. 6.0; p < 0.01), and higher rates of use of transapical access. Furthermore, most were extreme- or high-risk patients.


Read also: Aortic Stenosis with Normal Flow Low Gradient: Should We Intervene or Wait?


The hospital stay for this group was longer (9 days vs. 5 days; p =< 0.01).

 

The factors related with the development of NAF were ejection fraction, age, COPD, and non-transfemoral access (4.4% transfemoral access vs. 16.5% non-transfemoral access; p < 0.01).

 

As regards in-hospital indicators, these patients had higher rates of mortality (7.8% vs. 3.4%; p < 0.01), stroke (4.7% vs. 2.0%; p < 0.01), and major bleeding (10.6% vs. 6.1%; p < 0.01). There were no differences in all other events.


Read also: What to Do with Blood Pressure Levels Between 130/80 and 139/89 mmHg.


Despite having a CHA2DS2-VASc score of 5, less than 30% of patients received anticoagulation after discharge. About half the patients received anti-arrhythmia medication and there was a trend towards higher rates of beta-blocker prescription.

 

At 1 year, there were higher rates of mortality (33.8% vs. 20.7%; p < 0.01), stroke (7.5% vs. 6.3%; p < 0.01), major bleeding (30.1% vs. 35.7%; p < 0.01), and readmission due to heart failure (14.8% vs. 10.5%; p < 0.01). Mortality was similar among patients who received anticoagulation after discharge.

 

Conclusion

NAF after TAVR occurred in 8.4% of patients (4.4% with transfemoral access vs. 16.5%); less than a third received anticoagulation after discharge and it was associated with increased risk of in-hospital death and stroke at 1 year. Given the clinical significance of developing NAF after TAVR, additional studies are necessary to delineate an optimal treatment strategy for this high-risk population.

 

Editorial Comment

New-onset atrial fibrillation after TAVR is not a minor detail and it must be taken into account at the time of discharge, since it indicates that the patient in question has more comorbidities and, at the same time, that this arrhythmia must be treated and controlled in the future.

 

While anticoagulation is associated with higher rates of non-fatal bleeding, its lack of indication was associated with higher rates of stroke and death.

 

This registry showed that anticoagulant agents neutralize mortality at 1 year, although, in this case, only one study group received this medication. We should be more careful with this population, carrying out more intensive follow-up procedures to try and improve their progress.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis from the STS/ACC TVT Registry.

Reference: Amit N. Vora et al. J Am Coll Cardiol Intv 2018;11:1746-56.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...